Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1989 Jul;210(1):56–58. doi: 10.1097/00000658-198907000-00009

Treatment of 27 postoperative enterocutaneous fistulas with the long half-life somatostatin analogue SMS 201-995.

P Nubiola 1, J M Badia 1, F Martinez-Rodenas 1, M J Gil 1, M Segura 1, J Sancho 1, A Sitges-Serra 1
PMCID: PMC1357766  PMID: 2500900

Abstract

Twenty-seven patients with postoperative enterocutaneous fistulas were treated with parenteral nutrition and SMS 201-995 (100 micrograms/8 hours, subcutaneously), a long half-life somatostatin analogue. At the time SMS 201-995 was started, 11 patients had low output fistulas (less than 1000 ml/48 hours), 11 patients had high output fistulas (above 1000 ml/48 hours), and 5 patients had fistulas sitting in large abdominal wall defects. Within 24 hours of treatment, a mean reduction of 55% of the fistula output was observed. Fistula site or output before treatment had no influence on the magnitude of output reduction. Spontaneous closure was achieved in 77% of the patients after a mean of 5.8 +/- 2.7 days of treatment with this drug. Two patients died (7.4%). Pain at the injection site was referred by 15% of the patients but no other side effects were observed. Glucose intolerance was not observed. SMS 201-995 has been shown to be very useful in the conservative treatment of enterocutaneous fistulas because of its ability to rapidly reduce fistula output and accelerate spontaneous closure.

Full text

PDF
56

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arimura A., Sato H., Dupont A., Nishi N., Schally A. V. Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas. Science. 1975 Sep 19;189(4207):1007–1009. doi: 10.1126/science.56779. [DOI] [PubMed] [Google Scholar]
  2. Bloom S. R., Mortimer C. H., Thorner M. O., Besser G. M., Hall R., Gomez-Pan A., Roy V. M., Russell R. C., Coy D. H., Kastin A. J. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet. 1974 Nov 9;2(7889):1106–1109. doi: 10.1016/s0140-6736(74)90869-1. [DOI] [PubMed] [Google Scholar]
  3. Boden G., Sivitz M. C., Owen O. E., Essa-Koumar N., Landor J. H. Somatostatin suppresses secretin and pancreatic exocrine secretion. Science. 1975 Oct 10;190(4210):163–165. doi: 10.1126/science.1166308. [DOI] [PubMed] [Google Scholar]
  4. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973 Jan 5;179(4068):77–79. doi: 10.1126/science.179.4068.77. [DOI] [PubMed] [Google Scholar]
  5. Creutzfeldt W., Lankisch P. G., Fölsch U. R. Hemmung der Sekretin-und Cholezystokinin-Pankreozymin-induzierten Saft-und Enzymsekretion des Pankreas und der Gallenblasenkontraktion beim Menschen durch Somatostatin. Dtsch Med Wochenschr. 1975 May 16;100(20):1135–1138. [PubMed] [Google Scholar]
  6. Guillemin R., Burgus R. The hormones of the hypothalamus. Sci Am. 1972 Nov;227(5):24–33. doi: 10.1038/scientificamerican1172-24. [DOI] [PubMed] [Google Scholar]
  7. Hild P., Stoyanov M., Dobroschke J., Aigner K. La somatostatine dans le traitement médical des fistules du pancréas et de l'intestin grële. Ann Chir. 1982 Mar;36(3):193–196. [PubMed] [Google Scholar]
  8. Hill G. L., Bourchier R. G., Witney G. B. Surgical and metabolic management of patients with external fistulas of the small intestine associated with Crohn's disease. World J Surg. 1988 Apr;12(2):191–197. doi: 10.1007/BF01658053. [DOI] [PubMed] [Google Scholar]
  9. Kraenzlin M. E., Wood S. M., Neufeld M., Adrian T. E., Bloom S. R. Effect of long acting somatostatin-analogue, SMS 201 995, on gut hormone secretion in normal subjects. Experientia. 1985 Jun 15;41(6):738–740. doi: 10.1007/BF02012573. [DOI] [PubMed] [Google Scholar]
  10. Lins P. E., Efendić S., Hall K. Effect of 24-hour somatostatin infusion on glucose homeostasis and on the levels of somatomedin A and pancreatic and thyroid hormones in man. Acta Med Scand. 1979;206(6):441–445. doi: 10.1111/j.0954-6820.1979.tb13543.x. [DOI] [PubMed] [Google Scholar]
  11. Mulvihill S., Pappas T. N., Passaro E., Jr, Debas H. T. The use of somatostatin and its analogs in the treatment of surgical disorders. Surgery. 1986 Sep;100(3):467–476. [PubMed] [Google Scholar]
  12. Nubiola-Calonge P., Badía J. M., Sancho J., Gil M. J., Segura M., Sitges-Serra A. Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output. Lancet. 1987 Sep 19;2(8560):672–674. doi: 10.1016/s0140-6736(87)92452-4. [DOI] [PubMed] [Google Scholar]
  13. Sitges-Serra A., Jaurrieta E., Sitges-Creus A. Management of postoperative enterocutaneous fistulas: the roles of parenteral nutrition and surgery. Br J Surg. 1982 Mar;69(3):147–150. doi: 10.1002/bjs.1800690310. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES